Some medications are changed and broken down by the liver. Grape seed might decrease how quickly the liver breaks down some medications. Taking grape along with some medications that are changed by the liver might increase the effects and side effects of these medications. Before taking grape, talk to your healthcare provider if you take any medications that are changed by the liver.
Some of these medications that are changed by the liver include lovastatin ( Mevacor ), ketoconazole ( Nizoral ), itraconazole ( Sporanox ), fexofenadine ( Allegra ), triazolam ( Halcion ), and numerous others. Use grape cautiously or avoid in patients taking these drugs.
The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.
In the 13-week study involving 234 mg initiation dosing in subjects with schizophrenia, occurrences of induration , redness, or swelling, as assessed by blinded study personnel, were infrequent, generally mild, decreased over time, and similar in incidence between the INVEGA SUSTENNA® and placebo groups. Investigator ratings of injection pain were similar for the placebo and INVEGA SUSTENNA® groups. Investigator evaluations of the injection site after the first injection for redness, swelling, induration, and pain were rated as absent for 69-100% of subjects in both the INVEGA SUSTENNA® and placebo groups. At Day 92, investigators rated absence of redness, swelling, induration, and pain in 95-100% of subjects in both the INVEGA SUSTENNA® and placebo groups.